Nifty
:
18696.10
Sensex
:
62868.50
-116.40 (-0.62%)
-415.69 (-0.66%)
Nifty
Sensex
:
:
18696.10
62868.50
-116.40 (-0.62%)
-415.69 (-0.66%)

Lupin Ltd.

Pharmaceuticals & Drugs - Global

Rating :
40/99

BSE: 500257 | NSE: LUPIN

NSE BSE
776.00
02-Dec-2022
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 769.95
  • 779.00
  • 762.40
  • 770.30
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  956797
  •  7365.68
  •  972.40
  •  583.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 35,037.25
  • 512.85
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 37,783.28
  • 0.52%
  • 2.95

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 47.11%
  • 0.73%
  • 8.41%
  • FII
  • DII
  • Others
  • 13.81%
  • 27.40%
  • 2.54%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.46
  • 0.75
  • -0.86

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -20.99
  • -41.52
  • -38.64

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 77.41

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 25.55
  • -
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.28
  • 2.94
  • 3.11

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.61
  • 14.04
  • 14.64

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 22
Sep 21
Var%
Jun 22
Jun 21
Var%
Mar 22
Mar 21
Var%
Dec 21
Dec 20
Var%
Net Sales
4,145.52
4,091.33
1.32%
3,743.84
4,270.19
-12.33%
3,883.03
3,783.10
2.64%
4,160.93
4,017.36
3.57%
Expenses
3,692.53
5,415.18
-31.81%
3,579.90
3,342.62
7.10%
3,656.58
3,075.55
18.89%
3,791.10
3,238.62
17.06%
EBITDA
452.99
-1,323.85
-
163.94
927.57
-82.33%
226.45
707.55
-68.00%
369.83
778.74
-52.51%
EBIDTM
10.93%
-32.36%
4.38%
21.72%
5.83%
18.70%
8.89%
19.38%
Other Income
14.94
72.81
-79.48%
73.94
64.99
13.77%
57.05
58.22
-2.01%
34.06
21.17
60.89%
Interest
54.88
34.43
59.40%
42.78
33.47
27.82%
41.47
31.84
30.24%
33.40
30.92
8.02%
Depreciation
203.47
919.33
-77.87%
192.83
208.76
-7.63%
327.19
215.72
51.67%
203.43
244.32
-16.74%
PBT
209.58
-2,204.80
-
2.27
750.33
-99.70%
-85.16
518.21
-
167.06
524.67
-68.16%
Tax
75.11
-109.91
-
89.09
202.33
-55.97%
426.73
54.01
690.09%
-382.00
83.49
-
PAT
134.47
-2,094.89
-
-86.82
548.00
-
-511.89
464.20
-
549.06
441.18
24.45%
PATM
3.24%
-51.20%
-2.32%
12.83%
-13.18%
12.27%
13.20%
10.98%
EPS
2.85
-46.21
-
-1.96
11.95
-
-11.40
10.15
-
12.01
9.66
24.33%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Net Sales
15,933.32
16,405.48
15,162.96
16,836.56
16,751.37
15,804.15
17,494.33
14,139.03
12,770.01
11,286.57
9,641.30
Net Sales Growth
-1.41%
8.19%
-9.94%
0.51%
5.99%
-9.66%
23.73%
10.72%
13.14%
17.06%
 
Cost Of Goods Sold
6,649.37
5,780.84
4,854.28
4,962.72
4,436.67
4,733.76
4,660.97
3,893.70
3,806.16
3,485.50
3,221.50
Gross Profit
9,283.95
10,624.64
10,308.68
11,873.84
12,314.70
11,070.39
12,833.36
10,245.33
8,963.85
7,801.07
6,419.80
GP Margin
58.27%
64.76%
67.99%
70.52%
73.51%
70.05%
73.36%
72.46%
70.19%
69.12%
66.59%
Total Expenditure
14,720.11
16,190.24
12,596.08
14,362.21
14,082.44
12,656.64
13,001.19
10,453.68
9,150.42
8,283.78
7,371.41
Power & Fuel Cost
-
443.96
414.48
443.17
442.28
433.88
377.86
381.27
362.81
334.29
320.22
% Of Sales
-
2.71%
2.73%
2.63%
2.64%
2.75%
2.16%
2.70%
2.84%
2.96%
3.32%
Employee Cost
-
2,989.30
2,825.90
2,986.84
2,770.17
2,864.71
2,849.52
2,141.62
1,747.34
1,464.65
1,266.62
% Of Sales
-
18.22%
18.64%
17.74%
16.54%
18.13%
16.29%
15.15%
13.68%
12.98%
13.14%
Manufacturing Exp.
-
2,187.99
1,945.67
1,852.21
1,731.57
2,087.52
2,270.19
1,766.00
1,320.55
1,129.59
976.51
% Of Sales
-
13.34%
12.83%
11.00%
10.34%
13.21%
12.98%
12.49%
10.34%
10.01%
10.13%
General & Admin Exp.
-
3,490.62
1,218.42
1,456.46
3,302.60
1,219.96
1,509.56
1,195.98
806.87
810.53
692.06
% Of Sales
-
21.28%
8.04%
8.65%
19.72%
7.72%
8.63%
8.46%
6.32%
7.18%
7.18%
Selling & Distn. Exp.
-
1,096.10
1,026.40
1,080.45
1,206.60
1,150.61
1,049.48
870.29
835.48
775.26
709.62
% Of Sales
-
6.68%
6.77%
6.42%
7.20%
7.28%
6.00%
6.16%
6.54%
6.87%
7.36%
Miscellaneous Exp.
-
201.43
310.93
1,580.36
192.55
166.20
283.61
204.82
271.21
283.96
709.62
% Of Sales
-
1.23%
2.05%
9.39%
1.15%
1.05%
1.62%
1.45%
2.12%
2.52%
1.92%
EBITDA
1,213.21
215.24
2,566.88
2,474.35
2,668.93
3,147.51
4,493.14
3,685.35
3,619.59
3,002.79
2,269.89
EBITDA Margin
7.61%
1.31%
16.93%
14.70%
15.93%
19.92%
25.68%
26.07%
28.34%
26.60%
23.54%
Other Income
179.99
213.67
136.29
483.76
333.01
150.35
106.51
185.19
239.75
116.48
27.85
Interest
172.53
142.77
140.64
362.98
302.49
204.35
152.53
59.47
9.81
26.65
40.95
Depreciation
926.92
1,658.71
887.41
970.22
846.05
1,085.87
912.23
487.13
434.70
260.97
332.19
PBT
293.75
-1,372.57
1,675.12
1,624.91
1,853.40
2,007.64
3,534.89
3,323.94
3,414.83
2,831.65
1,924.60
Tax
208.93
137.15
448.52
1,146.56
901.69
288.46
978.51
1,059.34
970.40
962.15
584.16
Tax Rate
71.13%
-9.99%
26.78%
131.36%
59.58%
53.10%
27.68%
31.87%
28.42%
33.98%
30.35%
PAT
84.82
-1,528.40
1,215.20
-273.72
611.73
247.74
2,549.21
2,255.84
2,403.24
1,836.37
1,314.16
PAT before Minority Interest
68.01
-1,509.72
1,226.60
-273.72
611.73
254.83
2,556.38
2,264.60
2,444.43
1,869.50
1,340.44
Minority Interest
-16.81
-18.68
-11.40
0.00
0.00
-7.09
-7.17
-8.76
-41.19
-33.13
-26.28
PAT Margin
0.53%
-9.32%
8.01%
-1.63%
3.65%
1.57%
14.57%
15.95%
18.82%
16.27%
13.63%
PAT Growth
113.22%
-
-
-
146.92%
-90.28%
13.00%
-6.13%
30.87%
39.74%
 
EPS
1.87
-33.61
26.73
-6.02
13.45
5.45
56.06
49.61
52.85
40.39
28.90

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Shareholder's Funds
12,153.27
13,803.14
12,536.70
13,742.23
13,577.06
13,497.57
11,163.37
8,874.06
6,931.57
5,204.18
Share Capital
90.90
90.74
90.60
90.50
90.42
90.32
90.12
89.90
89.68
89.51
Total Reserves
11,900.64
13,522.87
12,231.40
13,433.31
13,275.26
13,233.50
10,958.87
8,728.15
6,815.66
5,107.79
Non-Current Liabilities
1,153.07
1,136.03
3,003.18
7,296.41
6,876.13
6,446.96
6,032.39
426.15
507.16
572.87
Secured Loans
141.86
0.33
0.70
358.82
448.03
217.15
5.55
12.50
24.42
37.95
Unsecured Loans
0.00
15.79
1,792.58
6,282.90
5,976.47
5,430.63
5,368.35
89.33
126.54
209.11
Long Term Provisions
332.99
329.49
296.29
370.79
356.85
308.73
190.00
162.03
132.49
112.45
Current Liabilities
8,276.44
8,436.09
9,225.20
6,129.87
5,095.55
6,120.59
5,061.17
3,729.23
2,629.55
3,006.92
Trade Payables
2,282.91
2,014.44
2,412.30
2,498.18
2,575.40
2,588.90
1,988.82
1,956.06
1,594.13
1,542.88
Other Current Liabilities
1,394.11
2,766.67
3,124.23
1,279.82
1,517.16
657.97
1,001.27
829.76
287.64
381.25
Short Term Borrowings
3,702.30
3,049.44
2,492.75
1,580.21
451.76
2,304.33
1,745.41
369.15
402.38
726.82
Short Term Provisions
897.12
605.54
1,195.92
771.66
551.23
569.39
325.67
574.26
345.40
355.97
Total Liabilities
21,651.49
23,430.23
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
Net Block
7,381.62
7,880.76
7,938.11
11,086.71
10,361.99
11,032.93
8,716.96
4,368.19
3,355.60
3,000.17
Gross Block
15,990.30
14,726.75
14,160.50
15,731.88
13,859.86
12,395.30
9,212.07
6,644.59
5,283.90
4,684.21
Accumulated Depreciation
7,768.47
6,845.99
6,222.39
4,645.17
3,497.87
1,362.37
495.11
2,276.40
1,928.30
1,684.04
Non Current Assets
9,193.81
9,443.86
9,396.33
13,361.79
13,379.28
14,146.71
12,401.61
5,221.19
4,034.77
3,700.29
Capital Work in Progress
1,146.28
1,066.26
939.62
1,639.71
2,598.20
2,133.06
2,702.40
551.87
285.90
310.70
Non Current Investment
77.60
78.07
36.07
185.63
26.71
22.00
14.33
2.51
2.06
2.06
Long Term Loans & Adv.
572.41
405.79
409.58
402.61
383.00
950.76
960.22
274.20
372.99
387.36
Other Non Current Assets
15.90
12.98
72.95
47.13
9.38
7.96
7.70
0.32
0.00
0.00
Current Assets
12,457.68
13,986.37
15,413.21
13,853.58
12,209.54
11,952.93
9,887.40
7,832.35
6,100.45
5,143.13
Current Investments
822.40
2,376.81
2,338.25
2,109.86
234.86
2,114.13
2.02
1,655.89
176.41
0.00
Inventories
4,630.73
4,092.01
3,456.87
3,836.77
3,662.49
3,642.28
3,273.65
2,503.56
2,129.45
1,948.93
Sundry Debtors
4,261.94
4,474.32
5,445.93
5,149.80
5,192.21
4,307.34
4,548.76
2,656.57
2,464.10
2,186.99
Cash & Bank
1,098.13
1,742.46
2,454.30
987.20
1,408.03
698.17
821.75
481.35
797.50
434.88
Other Current Assets
1,644.48
556.89
537.33
777.47
1,711.95
1,191.01
1,241.22
534.98
532.99
572.33
Short Term Loans & Adv.
1,112.46
743.88
1,180.53
992.48
1,090.65
657.58
761.78
294.91
275.15
339.67
Net Current Assets
4,181.24
5,550.28
6,188.01
7,723.71
7,113.99
5,832.34
4,826.23
4,103.12
3,470.90
2,136.21
Total Assets
21,651.49
23,430.23
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Cash From Operating Activity
367.31
1,821.76
1,468.84
1,665.97
1,751.19
4,113.51
-382.39
2,733.05
2,003.93
1,250.96
PBT
-1,372.21
1,676.45
876.78
1,517.17
546.81
3,543.14
3,328.84
3,414.83
2,831.65
1,924.60
Adjustment
1,707.68
1,033.16
1,574.29
1,588.41
2,782.23
1,214.74
585.35
356.73
410.50
419.58
Changes in Working Capital
-15.04
-192.49
-471.02
-500.19
-1,019.43
504.62
-3,126.44
-94.91
-466.31
-549.35
Cash after chg. in Working capital
320.43
2,517.12
1,980.05
2,605.39
2,309.61
5,262.50
787.75
3,676.65
2,775.84
1,794.83
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
46.88
-695.36
-511.21
-939.42
-558.42
-1,148.99
-1,170.14
-943.60
-771.91
-543.87
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
1,292.23
-1,239.58
1,106.99
-3,282.47
469.87
-2,527.44
-6,961.71
-1,054.51
-858.54
-521.86
Net Fixed Assets
-471.44
-693.00
-481.49
-462.56
-1,394.31
-876.24
480.96
-416.45
-309.36
-324.79
Net Investments
51.49
-2,106.15
-67.96
-2,025.62
1,551.07
-3,173.10
-296.59
-2,280.57
-475.62
-0.75
Others
1,712.18
1,559.57
1,656.44
-794.29
313.11
1,521.90
-7,146.08
1,642.51
-73.56
-196.32
Cash from Financing Activity
-1,572.32
-1,885.27
-890.58
744.13
-1,492.10
433.18
5,836.38
-196.89
-857.11
-662.82
Net Cash Inflow / Outflow
87.22
-1,303.09
1,685.25
-872.37
728.96
2,019.25
-1,507.72
1,481.65
288.28
66.28
Opening Cash & Equivalents
926.22
2,229.31
544.06
1,416.43
687.47
780.22
2,095.06
606.62
310.93
244.65
Closing Cash & Equivalent
1,013.44
926.22
2,229.31
544.06
1,416.43
2,799.47
780.22
2,108.43
606.62
310.93

Financial Ratios

Consolidated /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Book Value (Rs.)
263.84
300.06
272.01
298.87
295.64
295.04
245.21
196.17
154.00
116.13
ROA
-6.70%
5.09%
-1.05%
2.32%
0.99%
10.57%
12.82%
21.08%
19.70%
15.98%
ROE
-11.79%
9.46%
-2.12%
4.55%
1.91%
20.98%
22.80%
31.09%
30.89%
29.12%
ROCE
-7.11%
9.70%
6.02%
8.45%
3.54%
18.53%
24.38%
40.30%
40.97%
32.70%
Fixed Asset Turnover
1.97
1.96
2.10
1.93
2.07
1.63
1.80
2.16
2.28
2.19
Receivable days
52.62
64.06
61.62
66.11
63.76
91.82
92.24
72.65
74.67
74.61
Inventory Days
52.54
48.75
42.41
47.94
49.03
71.70
73.96
65.73
65.48
69.24
Payable days
132.55
161.68
65.89
68.49
68.56
60.60
63.20
64.43
63.78
63.76
Cash Conversion Cycle
-27.39
-48.88
38.14
45.56
44.23
102.92
103.00
73.94
76.37
80.10
Total Debt/Equity
0.32
0.35
0.51
0.63
0.53
0.60
0.65
0.06
0.09
0.22
Interest Cover
-8.61
12.91
3.40
6.00
3.66
24.18
56.89
349.10
107.25
48.00

Annual Reports:

FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013

News Update:


  • Lupin launches Formoterol Fumarate Inhalation Solution
    29th Nov 2022, 14:06 PM

    Formoterol Fumarate Inhalation Solution (RLD Perforomist) had estimated annual sales of $268 million in the U.S.

    Read More
  • Lupin's Brazilian subsidiary acquires rights to nine brands from Bausch Health
    28th Nov 2022, 18:24 PM

    This move reinforces the company’s commitment to making healthcare solutions accessible to all patients

    Read More
  • Lupin gets USFDA’s observations for Mandideep Unit-1 facility
    24th Nov 2022, 15:57 PM

    The inspection of the facility closed with issuance of a Form 483 with eight observations

    Read More
  • Lupin’s CSR arm inks MoU with Government of Rajasthan
    21st Nov 2022, 16:58 PM

    LHWRF will work with the State’s Department of Health and Family Welfare for strengthening the healthcare system

    Read More
  • Lupin turns black in Q2FY23
    10th Nov 2022, 11:18 AM

    Total consolidated income of the company decreased by 0.09% to Rs 4,160.46 crore for Q2FY23

    Read More
  • Lupin - Quarterly Results
    9th Nov 2022, 20:11 PM

    Read More
  • Lupin receives tentative approval from USFDA for Doxycycline Capsules
    8th Nov 2022, 14:58 PM

    Doxycycline Capsules had estimated annual sales of $215 million in the U.S.

    Read More
  • Lupin receives tentative approval from USFDA for Drospirenone Tablets
    4th Nov 2022, 12:39 PM

    Drospirenone Tablets had estimated annual sales of $141 million in the U.S.

    Read More
  • USFDA issues warning letter to Lupin’s Maharashtra-based API plant
    3rd Nov 2022, 09:56 AM

    A warning letter is issued when the US health regulator finds that a manufacturer has significantly violated its regulations

    Read More
  • Lupin gets USFDA’s observations for Nagpur Unit-2 facility
    31st Oct 2022, 09:45 AM

    The inspection closed with issuance of a Form-483 with five observations

    Read More
  • Lupin launches Paliperidone Extended-Release Tablets in United States
    20th Oct 2022, 16:04 PM

    Paliperidone Extended-Release Tablets had estimated annual sales of $112 million in the U.S.

    Read More
  • USFDA concludes prior-approval inspection at Lupin’s Biotech manufacturing facility
    20th Oct 2022, 10:06 AM

    The inspection concluded with the issuance of a Form 483 with seventeen observations

    Read More
  • Lupin’s arm signs definitive agreement to acquire two inhalation medicines
    20th Oct 2022, 09:24 AM

    The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S. and strengthens the company’s presence in the respiratory therapy area

    Read More
  • Lupin partners with global agencies to increase patient access to TB prevention treatment
    7th Oct 2022, 15:27 PM

    Through this agreement, Lupin will introduce two new formulations

    Read More
  • Lupin gets approval from USFDA for Darunavir Tablets
    4th Oct 2022, 14:57 PM

    The product will be manufactured at Lupin’s facility in Nagpur, India

    Read More
  • Lupin gets EIR from US FDA for Ankleshwar manufacturing facility
    3rd Oct 2022, 09:49 AM

    The inspection of the facility was conducted from August 16-19, 2022

    Read More
  • Lupin gets nod from USFDA for Mirabegron extended-release tablets
    29th Sep 2022, 16:00 PM

    The product will be manufactured at Lupin’s facility in Nagpur, India

    Read More
  • Lupin launches Sildenafil for Oral Suspension in United States
    29th Sep 2022, 14:56 PM

    Sildenafil for Oral Suspension, 10 mg/mL, is a generic equivalent of Revatio for Oral Suspension, 10 mg/mL of Viatris Specialty LLC

    Read More
  • Lupin gets warning letter from USFDA for Tarapur facility
    29th Sep 2022, 10:59 AM

    The USFDA had inspected the Lupin Tarapur site from March 22, 2022 to April 4, 2022

    Read More
  • Lupin gets nod from USFDA for Diclofenac Sodium Topical Solution USP, 2% w/w
    22nd Sep 2022, 15:44 PM

    The product will be manufactured at Lupin’s facility in Pithampur, India

    Read More
  • Lupin receives Health Canada's approval for Rymti
    13th Sep 2022, 14:45 PM

    The company is committed to enhancing patient access to high-quality, life-enhancing biosimilars

    Read More
  • Lupin launches generic Suprep Bowel Prep Kit in United States
    9th Sep 2022, 12:08 PM

    Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution (RLD Suprep Bowel Prep Kit) had estimated annual sales of $202 million in the U.S.

    Read More
  • Lupin, DKSH ink agreement to market five Biosimilar candidates in Philippines
    7th Sep 2022, 12:28 PM

    According to the agreement, Lupin’s subsidiary in Philippines, Multicare Pharmaceuticals, will file for marketing approval

    Read More
  • Lupin’s arm recalls 7,872 bottles of Rifampin Capsules in US market
    5th Sep 2022, 10:52 AM

    The company is recalling the affected lot due to Current Good Manufacturing Practice deviations

    Read More
  • Lupin gets tentative approval from USFDA for Dasatinib Tablets
    29th Aug 2022, 16:20 PM

    Dasatinib Tablets (RLD Sprycel) had estimated annual sales of $1569 million in the U.S. (IQVIA MAT June 2022)

    Read More
  • Lupin launches Desvenlafaxine Extended-Release Tablets in United States
    26th Aug 2022, 17:59 PM

    Desvenlafaxine Extended-Release Tablets, 25 mg is a generic equivalent of Pristiq Extended-Release Tablets, 25 mg of PF PRISM C.V.

    Read More
  • Lupin’s UK subsidiary gets MHRA approval to market generic version of Spiriva
    26th Aug 2022, 12:40 PM

    Lutio has the potential to offer significant cost savings when available to UK patients

    Read More
  • Lupin enters into exclusive licensing agreement with I’rom Group Co in Japan
    25th Aug 2022, 12:46 PM

    Under the terms of the Agreement, I’rom will conduct clinical trials along with Lupin, register, distribute and market biosimilar Denosumab in Japan on an exclusive basis

    Read More
  • Lupin enters into Deed of Assignment to acquire brands ‘Ondero’, ‘Ondero - Met’
    25th Aug 2022, 09:45 AM

    The cost of acquisition of brands is euro 26 million

    Read More
  • Lupin gets USFDA’s nod for Formoterol Fumarate Inhalation Solution
    24th Aug 2022, 15:56 PM

    Formoterol Fumarate Inhalation Solution (RLD Perforomist) had estimated annual sales of $282 million in the U.S.

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.